Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Montana Mafia*
Chemotherapy plays a pivotal role in the comprehensive treatment of bone cancer, a rare and aggressive malignancy that poses significant challenges to patients and healthcare providers. As a systemic treatment, chemotherapy utilizes potent drugs to target and destroy rapidly dividing cancer cells, inhibiting tumor growth and preventing metastasis. In bone cancer treatment, chemotherapy serves multiple crucial functions, including neoadjuvant therapy to shrink tumors before surgery, adjuvant therapy to eradicate residual cancer cells post-surgery and palliative care to alleviate symptoms and improve the quality of life for advanced-stage patients. Through ongoing research and clinical advancements, chemotherapy for bone cancer has evolved, leading to more targeted and personalized therapies, thereby reducing side effects and enhancing treatment efficacy. Challenges persist; however, as bone cancer’s aggressive nature and potential drug resistance necessitate continued investigation and innovative approaches. The pursuit of further research, multidisciplinary collaboration, and precision medicine holds promise for continually refining chemotherapy’s role in bone cancer treatment, offering hope and improved outcomes for patients facing this formidable disease [1].